Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider
22. November 2024 09:00 ET
|
SNS Insider pvt ltd
Austin, United States, Nov. 22, 2024 (GLOBE NEWSWIRE) -- According to SNS Insider, The Genome Editing Market, valued at USD 7.99 billion in 2023 and is projected to reach USD 32.72 billion by 2032,...
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
16. November 2024 10:16 ET
|
Intellia Therapeutics, Inc.
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater...
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
07. November 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on...
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
31. Oktober 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November...
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
24. Oktober 2024 08:01 ET
|
Intellia Therapeutics, Inc.
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
21. Oktober 2024 10:54 ET
|
Research and Markets
Dublin, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical,...
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
07. Oktober 2024 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
01. Oktober 2024 07:30 ET
|
Intellia Therapeutics, Inc.
New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR...
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
12. September 2024 07:30 ET
|
Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
10. September 2024 04:51 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Therapeutics Market" report has been added to ResearchAndMarkets.com's offering.The gene editing therapeutics market is estimated to be...